Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities:
Net loss	$ (9,465,033)	$ (6,192,370)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization expense	64,597	28,331
Stock-based compensation	160,593	82,238
Warrants	33,154	179,231
Amortization of debt discount	1,477,895
Loss on debt modification	2,385,204
Change in fair value of derivative liability	(15,282)
Change in fair value of warrant liability	(438,972)
Leasing	2,885	38,050
Forgiveness of PPP loan and accrued interest	(408,242)
Increase (decrease) in cash attributable to changes in operating assets and liabilities:
Accounts receivable	821	(821)
Prepaid expenses	(14,613)	(152,429)
Other assets	(37,555)	(40,000)
Accounts payable	(754,509)	764,322
Accrued expenses	(292,400)	192,779
Accounts payable and accrued expenses, related party	367,473	12,500
Accrued Interest	127,991	82,983
Accrued Interest, related party	572,346	1,076,478
Other liabilities	(83,942)	12,639
Net cash used by operating activities	(6,317,589)	(3,916,069)
Cash flows from investing activities:
Purchase of property and equipment	(336,157)	(43,421)
Cash received with merge with Boston Therapeutics	63,362
Net cash used by investing activities	(272,795)	(43,421)
Cash flows from financing activities:
Proceeds from notes payable	410,000	250,000
Proceeds from notes payable, related party	290,000	2,732,000
Net proceeds from notes payable - related parties	50,000
Repayments of notes payable - related parties	(50,000)
Proceeds from Secured Promissory Notes	6,331,000
Proceeds from borrowing PPP loan		402,154
Proceeds from issuance of common stock	23,450
Proceeds from options exercised	20,375
Re-purchase of Nanomix common shares	(202,188)
Net cash provided by financing activities	6,872,637	3,384,154
Net increase (decrease) in cash	282,253	(575,336)
Cash at the beginning of the year	15,098	590,434
Cash at the end of the year	297,351	15,098
Non-cash investing and financing transactions:
Right-of-use asset obtained in exchange for lease obligations	(232,065)	(192,788)
Lease liability	229,180	154,738
Convertible notes payable for accrued expenses	62,500	75,000
Preferred stock conversion into common stock	40,070,108
Secured promissory note for related party for related party note payable	1,603,778
Common stock for convertible note payable	10,639,616
Discount for beneficial conversion feature and warrants issued with notes	$ 5,796,609